Slide the arrows to reveal the immune and tumor cells of a melanoma tumor.
A cancer diagnosis can feel overwhelming. Navignostics is developing advanced molecular analysis to give oncologists a more detailed picture of individual tumors, with the goal of supporting better-informed treatment decisions.
This page explains what we do, who can currently access our analysis, and how to find out whether it may be relevant to your situation.
Where we are in our development: Our analysis is currently classified as Research Use Only (RUO) and are not yet approved as a clinical diagnostic test by regulatory authorities. Access to our analysis is currently available within specific research programs at partner institutions in Switzerland and Europe. We are working towards full regulatory approval. If you are unsure whether this is relevant to your situation, please speak with your oncologist.
Every cancer is different. Even two patients with the same diagnosis can have tumors that behave very differently.
Standard pathology tells your doctor a lot, but it may not fully capture how your tumor is organized at a molecular level: which proteins and drug targets are present, how immune cells are interacting with tumor cells, and what could stop a treatment from being successful.
Think of it this way: standard tests can tell you which street names are in a town. Our analysis plots those streets on a map, showing how they intersect, whether they’re one-way, and where the dead-ends are. That level of detail can matter when your oncologist is deciding which treatment path to take.
Slide the arrows to reveal the immune and tumor cells of a melanoma tumor.
Navignostics is developing a diagnostic test that analyses your tumor using a technique called spatial single-cell proteomics.
In simple terms, we look at lots of different proteins at the same time inside your tumor. This includes cancer cells, immune cells, and the tissue surrounding them. We then create a map of your tumor that is far more detailed than what standard tests can provide.
The results are compiled into a report for your oncologist or pathologist. Navignostics does not prescribe treatments or make clinical decisions, all treatment decisions remain entirely with your treating oncologist.
1. Your oncologist sends us a small part of your already-taken biopsy sample to our central laboratory in Switzerland. No additional clinical procedures are necessary.
2. We measure and analyze your sample with our technology, creating a detailed map of all the immune and tumor cells and how they interact.
3. Your report is sent to your oncologist, who will discuss the findings with you in the context of your overall care. How findings inform your treatment is always determined by your oncologist.
In some cases, yes.
Navignostics analysis is not yet available as a standard test your doctor can simply order. However, if you have a solid tumor cancer, there may be a pathway to access our analysis within a research context with one of our research partners.
We are currently most active in late-stage research contexts in the following indications: lung cancer, colorectal cancer, melanoma and breast cancer.
The best starting point is to ask your oncologist whether they would be interested in collaborating with the doctors at our partner institutions to receive a Navignostics analysis.
You can ask them to reach out to us directly for more information.
The report may show molecular features relevant to targeted or immunotherapy approaches for your oncologist to weigh alongside other clinical information.
With the same information, oncologists may see features that suggest certain treatments may be less appropriate, helping to focus discussion on the most relevant options.
Your oncologist may see molecular characteristics that are relevant to clinical trials they will consider discussing with you.
These findings are provided to support your oncologist’s analysis, they are not a clinical recommendation on their own. Your doctor will interpret them in the context of your full clinical picture.
If you are looking for broader support as a patient or caregiver, the following independent organisations may be helpful:
Advice and support for people affected by cancer across Switzerland.
European Cancer Patient Coalition for patient advocacy across Europe.
Research partner of Navignostics at the University Hospital of Zürich.
Information on clinical trials available to patients in Switzerland.
Disclaimer: The information on this page is for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional regarding your medical condition and treatment options. Navignostics does not make clinical recommendations directly to patients.
Regulatory status: Navignostics analytical methods are classified as Research Use Only (RUO) and are not approved diagnostic devices. They are not intended to be used as the sole basis for clinical decisions. This applies in all jurisdictions including Switzerland, the EU, and the United States.